Executive interview – RhoVac

Executive interview – RhoVac

Chosa — 2 videos in collection

More on this equity

RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The ongoing Phase IIb study in prostate cancer is fully funded and results are expected around mid-2021. RhoVac’s strategic aim is to secure a partner for the late-stage development of RV001. In this video, Anders Månsson, RhoVac’s chief executive officer, introduces the company and its lead asset, RV001 and provides an overview of R&D progress and expected newsflow.


You may also be interested in these:

Healthcare

CHOSA Oncology – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.